Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults

NCT06822907

Status	RECRUITING
Phase	Phase 4
Sponsor	Centre Hospitalier Universitaire de Saint Etienne
Enrollment	1,052 participants

Key Eligibility Criteria

Inclusion (7)

- History of body temperature e 38°C measured at least twice prior to randomization (Randomization must be performed as soon as possible on a febrile patient or 72 hours after apyrexia at the latest)
- Having at least one comorbidity that defines patients as medium or high risk for pneumococcal invasive infection:
- Medium risk: Cyanogenic congenital heart disease; chronic heart failure; chronic respiratory failure; chronic obstructive pulmonary disease; emphysema; severe asthma under chronic treatment; chronic renal failure; chronic liver disease; diabetes mellitus treated; Osteo-meningeal leak or cochlear implant; Age \> 65 years old.
- High risk : Hypo or asplenic people; hereditary immunodeficiency syndromes; people living with HIV; solid organ transplanted; People under immunosuppressors (corticosteroids, biotherapy) for an auto-immune or an inflammatory chronic disease; patients with nephrotic syndrome
- Hospitalization for \> 24 hours long

... and 2 more (see full listing online)

Exclusion (18)

- Patient unable to give informed consent
- Curators, wardship
- History of previous vaccination with PCV-7 or PCV-13 or PCV-20
- History of PPV-23 in the previous year
- Patient having received another vaccination within one month prior to inclusion or planning another vaccination in the month after inclusion except for Influenza vaccine.

... and 13 more (see full listing online)

Locations (24 total)

CHU de Saint-Etienne, Saint-Etienne, France, France
Centre Hospitalier, Annecy, France
Centre Hospitalier Universitaire, Besançon, France
... and 21 more locations